Trillium Therapeutics Inc. (TRIL) Increases Again; Strong Momentum for Buyers

April 17, 2018 - By Louis Casey

The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) is a huge mover today! The stock increased 7.97% or $0.55 during the last trading session, reaching $7.45. About 406,273 shares traded or 440.88% up from the average. Trillium Therapeutics Inc. (NASDAQ:TRIL) has risen 12.70% since April 17, 2017 and is uptrending. It has outperformed by 1.15% the S&P500.
The move comes after 5 months positive chart setup for the $92.89 million company. It was reported on Apr, 17 by Barchart.com. We have $7.75 PT which if reached, will make NASDAQ:TRIL worth $3.72M more.

Analysts await Trillium Therapeutics Inc. (NASDAQ:TRIL) to report earnings on May, 11. They expect $-0.56 earnings per share, up 49.09 % or $0.54 from last year’s $-1.1 per share. After $-0.72 actual earnings per share reported by Trillium Therapeutics Inc. for the previous quarter, Wall Street now forecasts -22.22 % EPS growth.

Trillium Therapeutics Inc. (NASDAQ:TRIL) Ratings Coverage

Among 2 analysts covering Trillium Therapeutics (NASDAQ:TRIL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Trillium Therapeutics had 3 analyst reports since December 14, 2017 according to SRatingsIntel. The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) has “Buy” rating given on Thursday, December 14 by H.C. Wainwright. On Friday, April 13 the stock rating was initiated by Leerink Swann with “Hold”. The stock has “Buy” rating by H.C. Wainwright on Monday, March 12.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $92.89 million. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.